Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy vs upfront resection: A challenging choice in resectable pancreatic ductal adenocarcinoma.
Authors
Fatemeh Fekrmandi
Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Fatemeh Fekrmandi , Brendan Hagerty , Qian Liu , Tyce Schneider , Nadia Malik , Christos Fountzilas , Moshim Kukar , Leonid Cherkassky , Benjamin Calvo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 620)
DOI
10.1200/JCO.2024.42.3_suppl.620
Abstract #
620
Poster Bd #
J7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy is associated with improved outcomes in patients with stage 1A and 1B pancreatic cancer undergoing surgery: An NCDB study.
First Author: Noah Rozich
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world impact of initial treatment modality on survival outcomes in patients with stage I-III pancreatic ductal adenocarcinoma.
First Author: Ajay Prakash
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX.
First Author: So Heun Lee